Evidence map›Paper›PMID 35611350›Full record

ArticleOpen forum infectious diseases2022

Immune Activation in Primary Human Immunodeficiency Virus: Influence of Duration of Infection, Treatment, and Substance Use.

Trupti Gilada, Samuel R Schnittman, Edward White, Jacqueline Mercader, Yixin Wang, Sayan Dasgupta, Rogelio Valdez, Delia Pinto-Santini, Siavash Pasalar, Jorge Sanchez and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Trupti GiladaUnison Medicine and Research Centre, Mumbai, India.
Samuel R SchnittmanDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Edward WhiteVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Jacqueline MercaderDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Yixin WangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Sayan DasguptaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-5271-7247
Rogelio ValdezCase Western Reserve School of Medicine, Cleveland, Ohio, USA.
Delia Pinto-SantiniVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Siavash PasalarVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Jorge SanchezCentro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Pedro GonzalesAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Javier R LamaAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Rachel Bender IgnacioVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Ann DuerrVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Fred Hutch Cancer Center · USAsociación Civil Impacta Salud y Educación · PEUniversity of Washington · USCase Western Reserve University · USMassachusetts General Hospital · USNational University of San Marcos · PE

Funding

Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol UseR01DA040532 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUERR, ANN C · 2015 to 2019
$8.0M
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSMR01DA032106 · NIDA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUERR, ANN C · 2011 to 2015
$6.6M
Enhancing Resident Investigation and Career Advancement in Cardiovascular and Pulmonary ScienceR38HL143581 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BIBBINS-DOMINGO, KIRSTEN, HUANG, ALISON · 2018 to 2021
$1.4M
Determining the component causes of systemic immune activation that moderate HIV acquisition and establishment of the latent viral reservoirK23AI129659 · NIAID · UNIVERSITY OF WASHINGTON · PI BENDER IGNACIO, RACHEL ANN · 2017 to 2021
$868k
NHLBI NIH HHS R38 HL143581NIAID NIH HHS K23 AI129659NIDA NIH HHS R01 DA032106NIDA NIH HHS R01 DA040532
6 · The paper itself

Abstract

Background: Primary human immunodeficiency virus (HIV) is characterized by dynamic changes in viral load and innate and adaptive immune responses; it is unclear the extent to which time from acquisition to antiretroviral therapy (ART) initiation and substance use impact these immunologic changes. Methods: We studied plasma immune activation biomarkers, viral load, and CD4 Results: Compared to participants enrolled >30 days after HIV acquisition, participants enrolled during acute infection (≤30 days) had higher mean interferon (IFN)-γ and IFN-α2a (1.7-fold and 3.8-fold interquartile range [IQR] higher, respectively). Participants enrolled >30 days after HIV acquisition had higher mean baseline CD8 Conclusions: IFN-γ and other biomarkers are elevated during early primary infection, when exposure to HIV antigens is high. Immune activation decreased most quickly in those who started ART during acute/early primary infection. Higher CD8

Indexed as

antiretroviral therapy initiationinnate immunityMSMPeruprimary HIV infection

Identifiers

PMID35611350
PMCPMC9124591
OpenAlexW4220943789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.